Haloperidol Interactions

Apnea, coma, bradycardia, arrhythmia, heart arrest, and death have been reported with concomitant use.

Source: NLP:lorazepam

Avoid use; may prolong QT interval and increase risk of arrhythmias with anagrelide.

Source: NLP:anagrelide

Avoid concomitant use due to QT prolongation risk.

Source: NLP:anagrelide hydrochloride

Butyrophenone antipsychotics potentiate the CNS-depressant action of clonazepam.

Source: NLP:clonazepam

High intravenous doses of clonidine may increase arrhythmogenic potential (QT-prolongation, ventricular fibrillation) of high intravenous doses of haloperidol, though causal relationship unclear.

Source: NLP:clonidine hydrochloride

QT-prolonging drug with known torsades de pointes risk. Combined with fingolimod's QT prolongation and bradycardia effects, patients require overnight continuous ECG monitoring in medical facility.

Source: NLP:fingolimod

Potential for elevation of haloperidol levels with risk of toxicity.

Source: NLP:fluoxetine hydrochloride

Haloperidol serum levels may be decreased, resulting in worsening of schizophrenic symptoms and tardive dyskinesia development. Closely monitor if coadministration unavoidable.

Source: NLP:glycopyrrolate

Haloperidol serum levels may decrease when coadministered with glycopyrrolate, resulting in worsening schizophrenic symptoms and tardive dyskinesia development. Closely monitor if coadministration cannot be avoided.

Source: NLP:glycopyrrolate oral solution

Antipsychotic that prolongs QTc interval and increases risk for Parkinsonism, NMS, and akathisia when used concomitantly with tetrabenazine.

Source: NLP:tetrabenazine

Venlafaxine decreases oral-dose clearance of haloperidol by 42%, resulting in 70% increase in haloperidol AUC and 88% increase in Cmax.

Source: NLP:venlafaxine

Venlafaxine decreases haloperidol clearance by 42%, increases AUC by 70%, and increases Cmax by 88%, resulting in significantly elevated haloperidol exposure.

Source: NLP:venlafaxine hydrochloride

Haloperidol is a butyrophenone dopamine antagonist that results in decreased efficacy of bromocriptine mesylate.

Source: NLP:bromocriptine mesylate

CYP2D6 substrate antipsychotic. Bupropion inhibits CYP2D6, increasing haloperidol exposure. Dose reduction may be necessary.

Source: NLP:bupropion hcl er (xl)

CYP2D6-metabolized antipsychotic. Bupropion inhibits CYP2D6 and can increase haloperidol concentrations. Consider dose reduction.

Source: NLP:bupropion hydrochloride

Haloperidol increases plasma concentration of clomipramine.

Source: NLP:clomipramine hydrochloride

Haloperidol increases plasma concentration of clomipramine; close supervision and dosage adjustment recommended.

Source: NLP:clomipramine hydrochloride capsules

Butyrophenone that suppresses dopaminergic renal and mesenteric vasodilation induced by low-dose dopamine.

Source: NLP:dopamine hydrochloride

QT-prolonging drug associated with torsades de pointes risk in bradycardia. Patients should be monitored overnight with continuous ECG in a medical facility.

Source: NLP:fingolimod hcl

Potential for elevation of haloperidol levels.

Source: NLP:fluoxetine

May induce hyperammonemia. Monitor ammonia levels closely when used concomitantly in patients with UCDs.

Source: NLP:glycerol phenylbutyrate

Drug interactions may occur when hyoscyamine sulfate is used with haloperidol.

Source: NLP:hyoscyamine sulfate

Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol, decreasing cardioselectivity.

Source: NLP:metoprolol

Potent CYP2D6 inhibitor may increase metoprolol plasma concentration, decreasing cardioselectivity.

Source: NLP:metoprolol tartrate

Nefazodone decreased haloperidol apparent clearance by 35% with unknown clinical significance. Dosage adjustment of haloperidol may be necessary.

Source: NLP:nefazodone hydrochloride

Elevated haloperidol levels have been observed with coadministration.

Source: NLP:olanzapine and fluoxetine

May increase plasma ammonia level; monitor ammonia levels closely.

Source: NLP:sodium phenylbutyrate

Suspected of causing SIADH; may increase pressor and antidiuretic effects of vasopressin. Hemodynamic monitoring recommended.

Source: NLP:vasopressin

May cause SIADH, increasing pressor and antidiuretic effects of vasopressin. Hemodynamic monitoring recommended; adjust vasopressin dose as needed.

Source: NLP:vasopressin in 0.9% sodium chloride

Venlafaxine increases haloperidol AUC and Cmax. Caution recommended with co-administration.

Source: NLP:venlafaxine hydrochloride, extended release

No effect on pharmacokinetics or pharmacodynamics of zolpidem after single-dose administration.

Source: NLP:zolpidem tartrate

Antipsychotic drug haloperidol interacts with benztropine; interaction details referenced in WARNINGS section.

Source: NLP:benztropine

Antipsychotic drug with potential interaction; specific severity not detailed in provided text.

Source: NLP:benztropine mesylate

Concomitant administration resulted in increased serum haloperidol concentrations; clinical significance unclear.

Source: NLP:buspirone hydrochloride